Working for the United States of America
and You, as the investor
Sterling Phillips, Jr.
Interview conducted by:
Mr. Sterling E. Phillips, Jr. is President, Chief Executive Officer and Director of Hadron, Inc. His Professional management career has focused on building companies in the information technology, engineering and scientific services arenas. Most recently, Mr. Phillips held senior management positions with Federal Data Corporation, in both the Science and Engineering, and Corporate Marketing Groups. Previously, he was the Chief Operating Officer of TRI-COR Industries, Inc. and served as President of Business Development for Computer Sciences Corporation. He has led management teams responsible for acquisitions in several of his former positions. Mr. Phillips also held senior national and international marketing positions with IBM for nearly twenty years. Mr. Phillips holds a B.A. from the University of North Carolina.
CEOCFOinterviews Please tell us about Hadron, Inc.?
Mr. Phillips We are in two businesses. Our biggest business is consulting services provided principally to the U.S. defense department and intelligence agencies. Our consulting is generally in the area of engineering services or information technologies services. Our people are principally involved in assisting customers in the intelligence community with application development and development of specialized equipment for their mission. The second business area were in is a biotech business, which is a bit of a spin off from our work with the intelligence community. We have a subsidiary called Advanced Biosystems that is developing medical defenses for and treatment against biological warfare agents. We are fortunate to have as the president of that subsidiary an individual who used to be the head of the Soviet Unions biological warfare program before defecting to the U.S. in 1992. So he probably has more hands-on experience with biological warfare weapons and research in that area than almost anybody around. He is a medical doctor and he prefers being on the treatment side than on the offensive side so were working on the defensive method with some medications that could protect against biological warfare agents and others that might treat patients after an attack.
On one hand your company deals with the technical solutions and than on the
other hand you deal with the pharmaceutical end of it.
CEOCFOinterviews Is the
government your only customer or does this expand beyond the government?
ceocfointerviews.com does not purchase or
recommendation on stocks based on the interviews published.